ClinicalTrials.gg
Active, not recruitingNCT03643861Updated Oct 20, 2026

RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)

An interventional study of 5 Fraction Stereotactic Body Radiation Therapy in Breast Cancer, sponsored by University of Alabama at Birmingham. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment

How we know

Updated Oct 20, 2026Now Active, not recruitingPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Breast Neoplasms by University of Alabama at Birmingham — 7 open to participants now, 11 under way, none of them phase 3. Breast Neoplasms · University of Alabama at Birmingham.

Planned enrollment
18th of 42
40 · median 35
Started
2019
with 2 others
No phase
22 of 46
4 open now
Primary completion
2029-12
later than 9 of 10 live
Registered
26th of 46
by date

Among the 46 studies in Breast Neoplasms by University of Alabama at Birmingham, this one is the 18th largest by planned enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2019, is one of 22 with no phase, reaches primary completion later than 9 of the 10 other live ones, and was the 26th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 46 studies in Breast Neoplasms by University of Alabama at Birmingham are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Breast Neoplasms by University of Alabama at Birmingham, or all of them as a file.
02

Study summary

This study offers 5 fractions of radiation treatment through partial breast irradiation in patients with early stage breast cancer after having a lumpectomy.

Read the detailed description

This study offers 5 fractions stereotactic body radiotherapy for early stage breast cancer after patient undergoes a lumpectomy. The study aims to determine the safety and feasibility of delivering only 5 doses of radiation treatment rather than the longer schedule of treatments that is currently considered standard of care for breast cancer patients. Patients will be followed for 36 months (2 years) with follow-up appointments at 6, 12, 18, 24, and 36 months.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • SBRT
  • Breast cancer
  • Early stage
  • Radiation therapy
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven invasive mammary carcinoma, Invasive ductal carcinoma (IDC) or ductal carcinoma in situ (DCIS) of the breast. Medullary, papillary, mucinous (colloid) and tubular histologies are allowed.
  • Age>50.
  • Maximum pathologic tumor size \<2.0cm if invasive carcinoma or \< 2.5cm if pure DCIS.
  • Estrogen receptor (ER) positive (>10%).
  • Must be eligible for breast conservation therapy and receive a lumpectomy with pathologic margins of at least 2mm.
  • Must be clinically node negative by physical examination. Sentinel node dissection is not required, but if undertaken, the patient must be pathologically node negative.
  • Zubrod Performance Status 0-2.

Exclusion criteria

Exclusion Criteria:

  • Multifocal or multicentric cancer.
  • Reception of chemotherapy.
  • Pure invasive lobular histology.
  • Inability to clearly delineate lumpectomy cavity on post lumpectomy planning scan.
  • Measured maximum PTV of >124cc.
  • Lumpectomy cavity within 5mm of body contour.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    5 Fraction Breast Stereotactic Body Radiation Therapy

    This study will enroll patients that have a confirmed histology of early stage breast cancer. The patient will undergo a lumpectomy and will then receive partial breast 5 fractions stereotactic body radiation therapy at a dose of 6 gy for 5 fractions for treatment. Patients will be followed for 36 total months with specific follow-ups at 3, 6, 9, 12, 18, 24, and 36 months.

    Radiation: 5 Fraction Stereotactic Body Radiation Therapy

Interventions

  • Radiation5 Fraction Stereotactic Body Radiation Therapy

    Stereotactic body radiation therapy (SBRT) has gained favor in the treatment of select central nervous system, lung, and abdominal malignancies due to its ability to deliver highly conformal doses of radiotherapy while using sharp dose gradients to deliver comparatively lower doses to the surrounding normal tissue. Utilization of SBRT is more labor intensive than conventional fractionation and requires precise immobilization and localization techniques with daily image guidance with direct physician and physicist oversight for all treatments. While more labor intensive and often utilizing more advanced technologies, SBRT allows the advantage of reducing setup margins compared to conventionally fractionated treatment while being able to shorten overall treatment times due to the ability to safely dose escalate high risk areas

06

What researchers measure

Primary outcomes

  1. Toxicity levels of 5 fractions SBRT for partial breast irradiation assessed by CTCAE v4.0

    To determine the safety of 5 fractions SBRT for patients with early stage breast cancer after a lumpectomy. Safety will be determined by CTCAE v4.0 and access toxicity, or lack of, experienced by patients enrolled in this study.

    Time frame: 0-2 years

Secondary outcomes

  1. Toxicity of breast SBRT using CTCAE v4.0

    To define the acute (\<90 days) and late toxicity (\>90 days) up to two years after breast SBRT (CTCAE 4) attributable to therapy.

    Time frame: 0-2 years

  2. Cosmetic outcome baseline and post-SBRT

    To determine patient and nurse assessed cosmetic outcome at baseline and 1, 6, 12, 18, 24, and 36 months post SBRT. Patient will give a verbal satisfaction rating of 1-Excellent, 2-Good, 3-Fair, or 4-Poor of their cosmetic appearance post-SBRT. Nurse will also give their overall rating of 1-Excellent, 2-Good, 3-Fair, or 4-Poor based off of their examination of the cosmetic appearance post-SBRT.

    Time frame: 0-2 years

  3. Patient reported outcome baseline and post-SBRT

    To determine patient reported outcome at baseline and 1, 6, 12, 18, 24, and 36 months post SBRT. The Quality of Life Breast Cancer Questionnaire (QLQ-BR45) is a 45-item questionnaire is composed of 45 questions with scale of 4 options where 1 represents "not at all" to 4 "very much". Scores on the QLQ-BR45 range from 45 to 180, with a lower score representing a higher quality of life.

    Time frame: 0-2 years

07

Study locations

2 sites
08

References and documents

Publications

  • Liu Y, Veale C, Hablitz D, Krontiras H, Dalton A, Meyers K, Dobelbower M, Lancaster R, Bredel M, Parker C, Keene K, Thomas E, Boggs D. Feasibility and Short-Term Toxicity of a Consecutively Delivered Five Fraction Stereotactic Body Radiation Therapy Regimen in Early-Stage Breast Cancer Patients Receiving Partial Breast Irradiation. Front Oncol. 2022 Jul 8;12:901312. doi: 10.3389/fonc.2022.901312. eCollection 2022. PubMed 35880164 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2019 (actual). Primary completion is estimated for Dec 2029, 123 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 123 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Dec 2027 → Dec 2029 and completion Dec 2028 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2018
First posted
Aug 23, 2018
StartActual
Aug 20, 2019
Primary completionEst.
Dec 1, 2029was Dec 2027
CompletionEst.
Dec 1, 2029was Dec 2028
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 20, 2026
Sites
1 site added
Show site
  • The Kirklin Clinic at Acton Road · Birmingham, United States
Oct 13, 2026
Primary completion
Dec 2027→Dec 1, 2029
Oct 13, 2026
Study completion
Dec 2028→Dec 1, 2029
Oct 13, 2026
Contact
Study contact's phone or email changed: d•••@uabmc.edu→d•••@uabmc.edu; •••5581→•••5581. See the current contact
Oct 13, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center (HSROC) · Birmingham, United StatesContact added d•••@uabmc.edu · •••5670
Oct 13, 2026
Show all 2 updates
  1. Oct 20, 2026
    Recruiting→Active, not recruiting
    + 2 other changes: contact details and site details
  2. Oct 13, 2026
    1 site added
    Show site
    • The Kirklin Clinic at Acton Road · Birmingham, United States
    Primary completion Dec 2027→Dec 1, 2029
    Study completion Dec 2028→Dec 1, 2029
    Contact Study contact's phone or email changed: d•••@uabmc.edu→d•••@uabmc.edu; •••5581→•••5581. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center (HSROC) · Birmingham, United StatesContact added d•••@uabmc.edu · •••5670
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03643861
Responsible party
Drexell Hunter Boggs (Radiation Oncologist, University of Alabama at Birmingham) — Principal investigator
First posted
Aug 23, 2018
Start date
Aug 20, 2019
Primary completion
Dec 1, 2029 (estimated)
Completion
Dec 1, 2029 (estimated)
Last update
Oct 20, 2026

Study contacts

D. Hunter Boggs, MD
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion